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A successful formulation (penciclovir hydrogel nanoemulsion) to be used in transdermal drug delivery route to treat herpes simplex 
virus was developed and an analytical method to quantify penciclovir (PCV) in porcine ear skin was stablished and validated. PCV 
nanoemulsions were prepared by high pressure homogenization and presented spherical mean droplet size 180 nm. The association 
efficiency and zeta potential were 87% and– 27 mV, respectively. The bioanalytical method developed showed specificity for the 
skin matrixes interferences (epidermis and dermis) and the linearity was in the range 0.1 – 25 μg/mL of drug. The mean recovery 
data for the three levels tested were 95.2% for the epidermis and 97.3% for the dermis and adequate results were obtained for 
repeatability and inter-day precision.  In vitro percutaneous absorption studies with penciclovir hydrogel nanoemulsion (HN) and a 
market cream were conducted employing porcine skin. The PCV cumulative amounts permeated from cream and HN, 8 hours after 
dosing, were 2.60 and 4.15 μg/cm², respectively, representing a quite higher flux and a much higher permeability coefficient for the 
developed formulation. It can be concluded that HN provide a good skin targeting effect and may be a promising carrier for topical 
delivery of penciclovir. 
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Introduction  
 
Herpes simplex virus (HSV) is etiological agent behind a 
common skin disorder characterized by mucocutaneous 
lesions. Penciclovir (PCV) is an acyclic nucleoside analogue 
used to treat herpes virus, with efficacy against HSV type 1 
and 2.  Due to its poor oral bioavailability (5 – 10 %) and to 
the fact that lesions are located in the skin, topical application 
remains as the delivery route of choice, although numerous 
herpes virus systemic therapies have been developed (1,2). 
Even though cutaneous application is a common herpes 
treatment route, antivirals should be able to achieve 
therapeutic concentrations in basal epidermic cells, which are 
the development site for the virus. This is one of the main 
limitations of this type of treatment, largely due to poor drug 
penetration across the stratum corneum (3,4).  
The development of topical formulations containing lipid-
based colloidal carriers are a promising approach to overcome 
this limitation and promote more effective penetration of 
antiviral drugs through the skin and thus to reduce the 
frequency of application (4,5). 
Nanoemulsions have large interfacial area and small droplet 
size, which are attractive characteristics for applications in 
pharmaceutical and cosmetics industries (6,7). One of the 
nanoemulsions advantages is the large production scale 
possibility by high pressure homogenization. This technology 
can be summarized in three steps: (1) formation of pre-
emulsion; (2) pre-dispersion homogenized by the high-
pressure homogenizer at a low pressure several times, and (3) 
homogenization at a high pressure for a sufficient number of 
cycles so that nanoemulsions achieve the desired size (8,9). 
Moreover, this technique is fast, simple and reliable for 
nanoemulsions preparation, apart from the capacity to 
incorporate drugs that are difficult to solubilize in aqueous 
and organic solvents, such as PCV (logP -1.62) (9,10). In 
spite of the fact that many anti-herpes drugs have been 
incorporated in nanoemulsions, penciclovir has not been 
evaluated (11,12).  
To evaluate the performance of new semisolid formulations 
with respect to the release, penetration and absorption of 
drugs in and/or through the skin the in vitro percutaneous 
absorption studies are conducted employing Franz diffusion 
cell and a cutaneous tissue model (13).  
Drug retention or permeation in the skin after the in vitro 
percutaneous absorption studies can be evaluated based on 
analytical quantification method previously validated, so as 
to ensure and to demonstrate the quality of the results, since 
the lack of reliable analytical data may lead to misleading 
decisions (14). 
The aim of this study was to develop nanoemulsions 
containing PCV for herpes simplex treatment and develop a 
liquid chromatographic method applied to drug quantification 
in porcine skin layers as well as to conduct in vitro 
percutaneous absorption studies for the formulation 
developed compared to a commercial cream. 
 
Materials and Methods 
 
PCV was obtained from EMS (São Paulo, Brazil). Egg-
lecithin (Lipoid E-80®) and medium chain triglycerides 
(MCT) were obtained from Lipoid GmbH (Ludwigshafen, 
Germany). Poloxamer 188 was obtained from Vetec (Rio de 
Janeiro, Brazil) and carbomer 940 was purchased from Sigma 
(São Paulo, Brazil). PCV commercial formulation at 
concentration 1% (w/w) was obtained from a local pharmacy. 
All the others reagents used in this work were HPLC grade. 
Acetonitrile and methanol were purchased from Tedia 
(Fairfield, USA) and the phosphoric acid from Merck 
(Darmstadt, Germany). Purified water was obtained by a 
Millipore® Direct-Q 3UV (Molsheim, France). The porcine 
ears were obtained from Ouro do Sul slaughterhouse 
(Harmonia, Brazil). 
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LC method 
 
The LC apparatus consisted of a Shimadzu LC-10A system 
(Kyoto, Japan) equipped with a model LC-20AT pump, a 
SPD-20AV UV-VIS variable wavelength detector (set at 251 
nm), a degasser DGU-20A5, a CBM-20A system controller, 
and SIL-20A injection valve with a 100 μL loop. PCV was 
analyzed using a Phenomenex C8 column (5 μm, 250 mm x 
4.6 mm i.d.) and Phenomenex C8 security guard (4 x 3.0 
mm). The selected phase consisted of a methanol:water 
mixture (7:93 w/w) in isocratic mode. Flow rate of 1 mL/min 
and an injection volume of 60 μL at room temperature were 
employed. 
 
Skin Preparation 
 
The porcine ears were obtained from a local slaughterhouse 
(16 – 18 hours after slaughter). The pig ears were washed with 
water and the skin of central region from the outer side of the 
ear was excised using a scalpel. After that, they were packed 
in polyvinyl chloride film and aluminum foil, stored at -20 °C 
and used within one month (15). 
 
Penciclovir Extraction Procedure  
 
For extraction procedure development, pig ear skin samples 
were sectioned in slices of 1.5 cm of diameter (equivalent to 
contact area with the formulation in the Franz cells). The skin 
layers were separated according to the following procedure: 
the skin circles were submerged in water at 60 oC for 45 
seconds, then epidermis and dermis layers were separated 
with a scalpel, cut into small pieces and placed in different 
tubes. Next, known amounts of the penciclovir (PCV) 
solution were poured over the tissues. After impregnation 
time and solvent evaporation (around 4 hours), 4 mL of 
extractor solvent - water or HCl 0.1M - were added, resulting 
in theoretical concentration final of 12.5 and 25 μg/mL. 
Different extraction times (20, 30 and 45 minutes) by 
ultrasound were tested. After that, the solution was filtered 
into vials and analyzed by HPLC.  
 
LC Method Validation 
 
The PCV quantification method in porcine skin samples was 
validated according to ICH guideline (16). For specificity 
evaluation, the chromatograms without and with PCV 
addition at epidermis and dermis obtained after extraction 
procedure were compared. Similarly, the specificity method 
for the formulations was assessed by comparing the 
chromatograms obtained from the products containing PCV 
and from blank formulation (placebo). 
Linearity was evaluated in the range 0.1 - 25 µg/mL by seven 
drug concentrations prepared in three different days. The final 
dilution of each volumetric flask was done with water spiked 
with porcine skin (epidermis and dermis) in the same 
proportion obtained during the extraction procedure (round 
skin of 1.5 cm diameter for each 8 mL of diluent). Linear 
regression was calculated by the least square regression 
method, and ANOVA was done to assess compliance to the 
linear model. The quantification and detection limits (LOQ 
and LOD, respectively) were formerly estimated based on 
standard curves (linearity). For the real quantification limits, 
three solutions (0.1, 0.05 and 0.03 μg/mL) were analyzed for 
precision and accuracy based on six injections for each 
concentration. 
The accuracy of the method was evaluated by PCV added to 
blank skin layer and its amount recovery.  Three different 
final concentrations (low, intermediate and high, 0.5, 12.5 
and 25 μg/mL, respectively) for each layer (epidermis and 
dermis) were prepared in triplicate for two consecutive days, 
resulting in six measurements for each level and each layer. 
Intra-day and inter-day precision were evaluated by RSD 
from accuracy results replicates. Additionally, carry-over was 
checked through three blank samples injection after a high 
level (25 μg/mL) sample analyze. 
 
Preparation of Penciclovir-loaded nanoemulsions 
 
Nanoemulsions O/W containing PCV were prepared using 
the high-pressure homogenization (HPH) method. The 
nanoemulsions oily phase was composed by MCT, egg-
lecithin and PCV; aqueous phase was composed by 
poloxamer 188 and water. The phases were heated 
individually at 60 оC, to complete solubilization of the 
components. After that, the phases were mixed and 
magnetically stirred for 5 minutes to form a pre-emulsion. 
Then, the pre-emulsion was submitted to HPH equipment at 
10,000 psi in 6 cycles (17). Blank formulations were prepared 
under the same conditions in absence of PCV and used as 
control. For hydrogels containing PCV-loaded 
nanoemulsions, carbomer 940 was dispersed in water and 
stirred at room temperature using a magnetic stirrer. After 
this, the mixture was neutralized to pH 6.0-7.0 with 
triethanolamine, to form the gel. Finally, 0.5 g of the 
carbomer gel was mixed with 4.5 g nanoemulsion with 
continuous stirring. The final composition (%, w/w) of 
nanoemulsions and hydrogel nanoemulsions obtained in 
presence or absence of poloxamer 188 are presented in Table 
1.  
 
Table 1. Final composition (%, w/w) of PCV-loaded nanoemulsions 
incorporated into hydrogels. 
 F1 F 2 
PCV 0.1 0.1 
MCT 8 8 
Egg-lecithin 2 2 
Poloxamer 188 - 1 
Water q.s.p 100 100 
Carbomer 940 0.5 0.5 
Thrietanolamine 0.2 0.2 
MCT: medium chain triglycerides 
 
Physicochemical characterization of nanoemulsions and 
hydrogels 
 
The nanoemulsions were characterized by mean droplet size 
(MDS), polydispersity index (PDI), zeta potential (ZP) and 
pH. MDS, PDI and ZP were determined by photon correlation 
spectroscopy (PCS) and electrophoretic mobility, 
respectively (3000HS Zetasizer, Malvern Instruments, 
England). All the samples were diluted to 0.4:200 (v/v) with 
1 mM NaCl before measurement. Also, pH was determined 
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directly in the bulk for each formulation using a pHmeter 
Digimed 20, and viscosity was determined using an Ostwald 
capillary viscometer at 20 оC. The nanoemulsions 
morphology was assessed by transmission electron 
microscopy (TEM). 
After incorporation of nanoemulsions into hydrogels, the 
morphological examination was also performed using TEM. 
Further, the rheological characterization of the hydrogel 
formulations were carried out using a Brookfield LVLD-II+ 
rotational viscometer at room temperature (25 ± 1 оC). 
 
Penciclovir content and association efficiency (AE) 
 
For PCV content determination, 500 μL of nanoemulsions 
was appropriately dissolved and diluted in methanol. An 
aliquot from the solutions was diluted in water, filtered and 
analyzed by liquid chromatography. For association 
efficiency, 500 μL of PCV-loaded nanoemulsions was placed 
into an ultrafiltration device (Amicon® Ultra-4, Millipore, 
Ireland) with a 30 kDa molecular weight cut-off which was 
centrifuged at 10,000 rpm for 10 min at 25 оC. The free drug 
amount in the external aqueous phase after separation from 
nanoemulsions was determined by liquid chromatography. 
The incorporated drug amount was calculated as  result of the 
initial drug minus free drug. The association efficiency (AE) 
was calculated according to the following equation:  
AE(%) = [(Winitial drug – Wfree drug) / Winitial drug] x 100% ; where 
“Winitial drug” is the amount of drug used for the assay and the 
“Wfree drug” is the amount of free drug quantified in the aqueous 
phase after isolation of the emulsion droplets. 
 
In vitro skin percutaneous absorption studies 
 
The suitability and the new formulation evaluation were 
performed in percutaneous absorption studies using a Franz 
type diffusion cell - area of 1.77 cm² with 7 mL of volume in 
the receptor compartment (Hanson Research, Chatsworth, 
USA) and porcine skin as membrane. The conditions 
employed for studies were: buffer phosphate pH 7.4 as 
receptor solution (PCV solubility is 1.3 mg/mL in 
physiological saline) at 32 o C and stirring at 500 rpm.  
The full-thickness porcine skin samples were mounted 
carefully on Franz-type diffusion cells with the stratum 
corneum side up the donor compartment and about 300 mg of 
test formulation (PCV hydrogel nanoemulsions or PCV 
market formulation) was placed on the skin surface in the 
donor compartment. The total experiment time was 8 hours 
and at given time intervals (1, 2, 4, 6 and 8 hours) receptor 
fluid aliquots of 1 mL were collected and the same volume 
were replaced. After 8 hours contact, the skin was removed 
from diffusion cell, the excess of formulation was carefully 
removed and the skin surface was gently cleaned with a wet 
swab. Immediately after, skin layers were separated by 
scapel, cut, weighed and submitted to the extraction 
procedure previously described. Only the skin area just in 
contact with the products was employed for extraction. 
The permeation flux J (μg/cm²/h) was determined employing 
the simplest approach by fitting the linear portion of the 
experimental curves for PCV permeated versus time and 
calculating the slope. To determine the permeability 
coefficient P (cm/h), the flux J was divided by the PCV 
concentration in the donor compartment Cdonor (μg/cm³) to 
normalize the different drug concentration of the products at 
starting time (18). 
 
Results and Discussion 
 
LC method and Penciclovir extraction procedure 
 
For PCV extraction procedure development from skin layers, 
two solvents in which the drug is soluble - water and 
hydrochloric acid - and different times of extraction (20, 30 
and 45 minutes) were tested. The results showed better, 
considering the recovery index and the polar similarity with 
the mobile phase of the chromatographic system, when using 
water as extractor solvent and 45 minutes was the time of 
extraction (data not shown). The analytical conditions 
employed allowed the adequate resolution of the PCV signal 
from the epidermis and dermis components, demonstrating 
specificity by the absence of interfering from biological 
matrix for each layer in the PCV retention time 
(approximately 10 minutes) (Figure 1). 
 
 
 
 
Figure 1. Specificity of the chromatographic system for PCV 
analysis in skin layers. A) Epidermis; B) Dermis. Black line is the 
blank of the skin layer; red is the skin layer with PCV 25 μg/mL. 
PCV retention time is 9.8 min. 
 
 
Satisfactory linearity could be obtained in the evaluated 
concentration range on each day during the experiment (r² = 
0.9999), and ANOVA showed non-significant linear 
deviation (p>0.05). LOQ and LOD were 0.1 and 0.03 μg/mL, 
respectively, when determined by estimation from the linear 
equations. When evaluated in the experimental assay, the 
concentrations tested (0.1, 0.05 and 0.03 μg/mL) presented 
0.3% and 113.2%; 4.2% and 89.4%; 4.5% and 64.4%, for 
RSD and accuracy, respectively, demonstrating that LOQ is 
minor the expected value, namely, 0.05 μg/mL. The accuracy 
of the analytical method is presented in terms of percentage 
recoveries of PCV added to biological matrix. Table 2 shows 
the mean data obtained for PCV recovery from skin layers 
(epidermis and dermis) and the values of relative standard 
deviation (RSD) for repeatability (intra-day) and intermediate 
precision for each level of PCV added to the matrixes.  
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Table 2. Accuracy and precision for PCV analysis in the skin layers 
by LC method 
E= epidermis; D= dermis; L= low; I= Intermediate; H= High; AR= Average 
recovery. 
 
The results are in accordance to the literature 
recommendations of overall recovery in the range of 85 –
115% for bioanalytical methods (16). The RSD values were 
also considered acceptable for a bioanalytical method 
(<15%), indicating the suitability of extraction process and 
analysis for quantification of PCV in the main skin layers. To 
ensure the accuracy (recovery) of the analytical method 
regarding skin sample preparation, a second extraction 
procedure was conducted with the same skin layers 
immediately after the first extraction. No more than 10% of 
the amount determined in the first extraction was found for 
both layers, demonstrating that the procedure was suitable for 
extraction of PCV retained in porcine skin layers (data not 
shown). Carry-over from the analytes was not observed at all. 
 
Formulation study 
 
Initially, six types of nanoemulsions were prepared with 
increasing PCV amounts. The formulations were obtained in 
the absence or presence of a non-ionic surfactant, poloxamer 
188. Firstly, 0.1% PCV nanoemulsions (F1 and F2) were 
prepared. In attempt to reach the PCV concentration in the 
commercial formulation (1%), nanoemulsions 0.5% and 1% 
were also prepared. However, these formulations proved to 
be unstable few hours after preparation, precipitating crystals 
overnight, even with the increase in additional surfactant 
(9,19). Therefore, F1 and F2 nanoemulsions were selected for 
further characterization studies. Table 3 exhibits the main 
physicochemical properties of blank (BF) and PCV-loaded 
nanoemulsions (F). 
 
Table 3. Physicochemical properties of blank (BF) and PCV-loaded 
nanoemulsions (F). 
F Size 
(nm) 
   PDI     ζ 
     (mV) 
   V 
      (cP) 
pH 
F1 212.6 
(± 1.79) 
0.163 
(± 0.01) 
  -26.9 
(± 0.90) 
0.83  
(± 0.004) 
6.39 
BF1 219.7 
(± 2.65) 
0.148 
(±0.02) 
  -27.1 
   (± 2.34) 
0.82 
(± 0.14) 
6.99 
F2 186.8  
(± 3.34) 
0.102  
(± 0.01) 
  -27.7 
(± 0.84) 
1.13 
(± 0.12) 
5.89 
BF2 190.3  
(± 4.25) 
0.078 
  (±0.02) 
  -26.1 
 (± 0.69) 
1.11 
(± 0.16) 
5.62 
1: nanoemulsion without poloxamer; 2: nanoemulsion with 
poloxamer; PDI: polydispersity index; V: Viscosity. 
Regardless of poloxamer 188 presence, mean droplet size was 
in the 180-220 nm range. F2 presented smaller size and pH 
than F1, which can be attributed to the presence of an 
additional surfactant, apart from egg lecithin. Adequate 
polydispersity index (lower than 0.17) was observed, 
showing a low deviation from the average size, where values 
up to 0.25 have been acceptable (20). The nanoemulsions 
presented ζ-potential about – 27 mV, indicating good stability 
of the formulations (17). Negative ζ-potential values are 
attributed to the presence of negatively charged 
phospholipids of egg lecithin in the final pH of the 
formulations. Moreover, the PCV incorporation into the 
nanoemulsions did not change ζ-potential values. 
The formulations exhibited low viscosity (F1: 0.82 cP; F2: 
1.13 cP), though F2 formulation viscosity was significantly 
higher (p<0.05) when compared to the value observed for F1 
(Table 3). Therefore, to favor nanoemulsions application on 
the skin is recommended that viscosity had been adjusted to 
reach a semisolid form. Thence, the nanoemulsions were 
incorporated into carbomer hydrogel. The final formulation 
(PCV hydrogel nanoemulsion - HN) shown to be non-
Newtonians fluids, since viscosity of fluid varies nonlinearly  
with shear rate without thixotropic behavior (data not shown) 
(21). Regarding the morphology, F2 nanoemulsions 
photomicrographs revealed spherical oil nanodroplets 
slightly larger than 150 nm in diameter, in accordance with 
the results obtained by dynamic light scattering (Figure 2).  
 
 
 
Figure 2. Photomicrographs of PCV loaded-nanoemulsions obtained 
from transmission electronic microscopy for F2 formulation before 
(A) and after (B) incorporation in hydrogel. 
 
Figure 2B shows individual oil droplets, despite their 
dispersion in the polymer network, exhibiting a droplet size 
quite similar to those detected before gel thickening, in turn 
indicating, under conditions applied in this study, that the 
nanoemulsions structure before being obtained as a semisolid 
preparation was in fact maintained. 
 
 
Penciclovir content and association efficiency (AE) 
 
PCV content was determined by liquid chromatography and 
the results for nanoemulsions and HN are presented in Table 
4.  
 
 
 
 
 
Skin 
layers 
PCV 
Level 
Day 1 Day 2 
Inter 
Day 
RSD 
AR 
(%) 
Intra 
Day 
RSD 
 
AR 
(%) 
(%)recovery 
Intra 
Day 
RSD 
 L 93.47 12.8 96.10 0.86 7.97 
E I 95.84 6.74 92.99 7.08 6.40 
 H 98.99 1.43 93.99 5.69 4.61 
  L 104.44 5.34 101.5 3.15 4.50 
D I 89.70 8.47 89.90 1.96 5.57 
 H 96.74 4.16 98.33 0.82 5.03 
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Table 4. PCV content (%)* in nanoemulsions and after 
incorporation in hydrogels (HN), at day 1 and after 30 days of 
storage at 4°C. 
 Nanoemulsions HN 
 Initial 30 days Initial 30 days 
F1 89.88  
(± 0.65) 
84.28  
(± 2.62) 
88.57  
(± 2.54) 
82.45  
(± 3.67) 
F2 95.83  
(± 2.70) 
92.39  
(± 3.96) 
94.27  
(± 1.69) 
91.27 
(± 0.28) 
*For a PCV theoretical concentration of 1 mg/mL. 
 
The F2 formulation presented quite higher PCV content than 
F1. This result was also observed for association efficiency, 
where F2 showed around 87% of the drug loaded into internal 
phase of the emulsion, while F1 presented around 75% of 
association. This result for F2 can be due to the presence of 
poloxamer 188 as stabilizer in addition to egg-lecithin (14). 
Therefore, F2 nanoemulsion was selected for further studies 
of cutaneous delivery. The commercial cream was also 
checked regarding PCV content and it was in accordance with 
the labeled dose. 
 
In vitro skin percutaneous absorption studies 
 
The PCV cumulative amount determined in the skin layers 
for each formulation is shown in Figure 3.  
 
 
Figure 3. Amount of extracted PCV from the skin layers expressed 
as μg/mg. *HN: hydrogel nanoemulsion. 
 
For epidermis and dermis, the PCV amounts retained, 
respectively, were 0.09 and 0.01 μg/mg for the cream and 
0.03 and 0.006 μg/mg for the F2-HN. The PCV percutaneous 
permeation profiles through porcine skin are shown in Figure 
4.  
 
Figure 4. Percutaneous permeation profiles of penciclovir from the 
hydrogel nanoemulsions and commercial cream through pig ear skin 
at time intervals 1, 2, 4, 6 and 8 hours. 
 
The drug flux (J) from the cream was 0.41 μg/cm²/h and from 
F2-HN was 0.77 μg/cm²/h leading to a permeability 
coefficient (P) of 4.10-5cm/h for the cream and 76.10-5cm/h 
for the developed formulation. The PCV cumulative amounts 
permeated from cream and F2-HN, eight hours after dosing 
were 2.60 and 4.15 μg/cm², respectively. These results were 
surprising as PCV concentration in cream is ten folds higher 
than in F2-HN. This observation might support the hypothesis 
that F2-HN has the tendency to have a higher passage through 
stratum corneum, as revealed by higher permeability 
coefficient, which makes it an attractive choice as the carrier 
for topical delivery of PCV.  
 
Conclusions  
 
The analytical method developed showed good specificity, 
accuracy and precision to measure PCV into porcine skin 
samples (epidermis and dermis). The method’s applicability 
to the work was proved through the evaluation of PCV skin 
retention and permeation from two formulations, commercial 
cream and hydrogel nanoemulsion developed. Furthermore, 
despite the minor PCV concentration in the new product, a 
higher skin permeability from hydrogel nanoemulsion was 
detected for the drug. 
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